Step 1 topics → Endocrine → Neuroblastoma

Neuroblastoma

USMLE Step 1 trap: Attributes midline-crossing abdominal mass in a child to Wilms tumor rather than neuroblastoma. Neuroblastoma classically crosses the midline because it arises from the adrenal medulla or paraspinal sympathetic ganglia; Wilms tumor (nephroblastoma) is intrarenal and typically does not cross the midline.

Neuroblastoma is a malignant tumor of primitive neural crest cells arising from the adrenal medulla or paraspinal ganglia, and it is the most common extracranial solid tumor in children under 5. USMLE Step 1 tests it from multiple angles, and students consistently confuse it with Wilms tumor — both present as abdominal masses in young children, but neuroblastoma crosses the midline and Wilms tumor stays intrarenal and unilateral. The exam also hits urinary metabolites, histologic features, and MYCN amplification as a prognostic marker that students routinely skip.

What makes neuroblastoma tricky is that several of its features superficially resemble other pediatric tumors. Students routinely confuse midline-crossing abdominal masses with Wilms tumor, mix up HVA versus VMA predominance when comparing to pheochromocytoma, and misidentify Homer-Wright pseudorosettes. The exam exploits these confusions heavily, often embedding the key distinguishing detail deep in a clinical vignette so you have to actually know the mechanism, not just the buzzword.

On USMLE Step 1, neuroblastoma questions tend to be passage-based with a child presenting with an abdominal mass, hypertension, or a paraneoplastic syndrome like opsoclonus-myoclonus ('dancing eyes, dancing feet'). The question then pivots to pathology, metabolites, or prognosis — requiring you to apply, not just recall. MYCN amplification as a prognostic marker is a particularly high-yield gap that students skip over, and it shows up in questions framed around staging or treatment decisions.

From real student decks
65%have cards covering this topic
35%have mature cards

Common misconceptions

Common mistake
Wrong: A pediatric abdominal mass that crosses the midline is more likely Wilms tumor than neuroblastoma.
Right: Neuroblastoma classically crosses the midline because it arises from the adrenal medulla or paraspinal sympathetic ganglia; Wilms tumor (nephroblastoma) is intrarenal and typically does not cross the midline.
Wilms tumor arises from renal parenchyma and expands within the kidney capsule — it pushes adjacent structures aside but stays unilateral and does not cross the midline. Neuroblastoma, by contrast, originates in the adrenal medulla or paraspinal ganglia and often wraps around the aorta or vena cava, allowing it to extend across the midline. On an abdominal CT in a child, a suprarenal mass crossing the midline is neuroblastoma until proven otherwise.
Common mistake
Wrong: Neuroblastoma and pheochromocytoma have identical urinary catecholamine metabolite profiles.
Right: Both elevate urinary HVA and VMA, but neuroblastoma predominantly elevates HVA (dopamine metabolite) while pheochromocytoma predominantly elevates VMA (epinephrine/norepinephrine metabolite).
Both tumors secrete catecholamines, but the specific metabolite profile differs because of the enzyme machinery each tumor expresses. Neuroblastoma cells predominantly produce dopamine and lack the enzymes to efficiently convert it to norepinephrine/epinephrine, so HVA (homovanillic acid, the dopamine metabolite) predominates. Pheochromocytoma cells have full sympathetic enzyme activity and produce norepinephrine and epinephrine, so VMA (vanillylmandelic acid) predominates. Both elevate both metabolites, but the ratio is the key discriminator.
Common mistake
Gap: Missing that MYCN amplification is a critical adverse prognostic marker in neuroblastoma
MYCN (N-myc) amplification in neuroblastoma is associated with rapid tumor progression and poor prognosis regardless of stage.
MYCN (N-myc) amplification is one of the most powerful adverse prognostic markers in pediatric oncology. Even a low-stage neuroblastoma with MYCN amplification is reclassified as high-risk and treated aggressively, because amplification correlates with rapid proliferation, treatment resistance, and early metastasis. On the exam, if a question gives you MYCN amplification status, it's almost always pointing toward poor prognosis — don't ignore it.
Common mistake
Wrong: Homer-Wright rosettes are specific to neuroblastoma among small-round-blue-cell tumors.
Right: Homer-Wright pseudorosettes (tumor cells surrounding neuropil, no central lumen) occur in neuroblastoma and medulloblastoma; true rosettes with a central lumen (Flexner-Wintersteiner) are seen in retinoblastoma.
The terminology here matters. Homer-Wright pseudorosettes in neuroblastoma and medulloblastoma consist of tumor cells arranged around a central core of neuropil (tangles of neural processes) — there is no open lumen. Flexner-Wintersteiner rosettes in retinoblastoma are true rosettes with a central lumen lined by photoreceptor-like cells. If the stem says 'no central lumen' or describes neuropil in the center, that's neuroblastoma/medulloblastoma territory, not retinoblastoma.
Free Deck audit

See if your Anki deck covers this topic.

Upload your deck →
Guided session

Stuck on this? An AI tutor that probes your understanding.

Start a session →

What the exam tests

  1. Recognize the classic presentation: a child under 5 with an abdominal mass that crosses the midline, possibly accompanied by opsoclonus-myoclonus or other paraneoplastic features.
  2. Know the diagnostic workup: elevated urinary HVA and VMA confirm catecholamine excess, imaging localizes the primary tumor, and MYCN amplification testing is essential for staging and prognosis.
  3. Identify neuroblastoma on histology as a small-round-blue-cell tumor with Homer-Wright pseudorosettes (tumor cells arranged around a central neuropil core, no true lumen).
  4. Distinguish neuroblastoma from pheochromocytoma (age, HVA vs VMA predominance, hypertensive urgency), Wilms tumor (intrarenal, does not cross midline), and retinoblastoma (Flexner-Wintersteiner true rosettes, eye).

Can you avoid these mistakes?

A 3-year-old presents with an abdominal mass that crosses the midline, mild hypertension, and intermittent jerky eye movements. Urinary catecholamine metabolites are elevated. What is the most likely diagnosis, and which specific metabolite would you expect to be most elevated?
On histology, you see sheets of small, dark, round cells with scant cytoplasm arranged around a central fibrillar core with no visible lumen. What is this structure called, and in what tumors does it appear?
A 4-year-old is diagnosed with neuroblastoma. Tumor testing reveals MYCN amplification. The tumor is otherwise stage 1 (localized, completely resected). How does the MYCN finding change management and prognosis?
A child has an abdominal mass on CT. The radiologist notes it is intrarenal and does not cross the midline. How does this imaging finding help differentiate Wilms tumor from neuroblastoma, and what histologic finding would you expect if this were Wilms tumor instead?

Related topics

Pheochromocytoma and Paraganglioma Hypothalamic-Pituitary-Adrenal (HPA) Axis Hypothalamic-Pituitary-Thyroid (HPT) Axis Hypothalamic-Pituitary-Gonadal (HPG) Axis Hormone Signaling (Peptide vs Steroid)

See how your Anki deck covers this topic.

Upload your deck for a free audit →